Field report W-95 / M2

Filed from the territory

FDA Orders Eye-Stroke Warning on GLP-1 Drugs Used by 30 Million Americans

The FDA now requires GLP-1 drugs taken by 30 million Americans to warn about NAION, a rare 'eye stroke' — trials show 2.6 extra cases per 100,000 patients per year.

Grid
W-95 / M2
Surveyed
November 17, 2026
Reading
4 min read
Correspondent
Priya Raman
GLP-1 drugs taken by 30 million Americans now carry an FDA warning for a rare ‘stroke of the eye’ that can cause vision
Fig. W-95 / M2GLP-1 drugs taken by 30 million Americans now carry an FDA warning for a rare ‘stroke of the eye’ that can cause vision — CommsEditors101 / pixabay

Field notes

  1. FDA ordered NAION warning labels for all GLP-1 drugs on November 9, 2026
  2. 126 clinical trials covering 134,253 patients showed 2.6 extra NAION cases per 100,000 GLP-1 users per year
  3. FDA Sentinel data (2019-2024) found 6 extra cases per 100,000 versus DPP-4 inhibitors
  4. A study of nearly 600,000 U.S. veterans found about 100 extra cases per 100,000 GLP-1 patients over three years
  5. European regulators classified NAION as a very rare semaglutide side effect in 2025

The FDA ruled on November 9, 2026 that every GLP-1 drug sold in the U.S. must carry a warning label for a rare eye condition that can cause permanent vision loss. The condition is non-arteritic anterior ischemic optic neuropathy, or NAION — doctors call it a stroke of the eye. Roughly 30 million Americans take GLP-1 medications (a drug class that mimics a gut hormone to control blood sugar and appetite), according to Gallup polling.

The stakes are enormous. These drugs treat diabetes and obesity, cut cardiovascular risk, and are under investigation for an expanding list of other conditions. The warning lands on one of the biggest drug classes in pharmaceutical history.

How big is the risk, in numbers?

Small, but measurable. That's the honest answer from the FDA's own data.

The agency first compiled results from 126 randomized, controlled clinical trials — the gold standard of drug evidence — covering 134,253 patients in total. Of those, 78,217 were on GLP-1 drugs and 56,036 received a placebo or a different medication.

The results, per year on average:

  • 6.4 cases of NAION per 100,000 people taking GLP-1 drugs
  • 3.8 cases per 100,000 among placebo or comparator groups
  • A net difference of 2.6 extra cases per 100,000 patients

The FDA then ran a second analysis through its Sentinel programs (a national network that tracks the real-world safety of approved medicines). It compared type 2 diabetes patients who started a GLP-1 drug against those starting other diabetes medications between 2019 and 2024.

Here the gap was wider. GLP-1 patients experienced NAION at 32 cases per 100,000 over one year, versus 26 per 100,000 for patients on DPP-4 inhibitors (drugs that prevent the breakdown of the body's natural GLP-1). That's 6 extra cases per 100,000.

What does the warning actually say about the condition?

NAION is an injury to the optic nerve, the cable connecting the eye to the brain. A sudden reduction in blood flow causes it. Patients typically notice sudden, painless blurry vision, dark patches, partial vision loss, or blindness.

There's a telltale pattern. Symptoms often appear first thing in the morning, because the condition tends to strike at night when blood pressure is naturally lower. And the damage usually persists, frequently producing permanent visual impairment.

Where did the evidence come from?

The FDA didn't start from scratch. A 2024 study of nearly 17,000 patients referred to ophthalmology clinics was the first to flag a potential link, reporting increased NAION risk among the subset prescribed a GLP-1 drug. Case reports began emerging as use surged after 2021, when the drugs won approval for obesity.

Independent real-world research — studies using electronic health records and insurance claims to track people over years — has found a consistent association.

One of the largest: researchers tracked nearly 600,000 U.S. veterans with type 2 diabetes over three years, comparing GLP-1 starters against patients on alternative drugs. The GLP-1 group showed roughly 390 NAION cases per 100,000 people, versus 290 per 100,000 on other medications. That's about 100 extra cases per 100,000 patients.

The numbers vary across studies, likely because patient groups differ — some populations were older or carried additional conditions that raise baseline risk.

One finding matters for prescribers: the elevated risk doesn't appear specific to any single GLP-1 drug. It can occur regardless of which one a patient takes. Whether some carry higher risk than others is an open question — no research addresses it yet.

What have other regulators done?

European regulators moved first. A 2025 review by the European Medicines Agency examined NAION risk in semaglutide (the molecule behind Ozempic, Rybelsus and Wegovy) and concluded the eye condition is a very rare side effect. It mandated that package inserts list NAION accordingly.

Two regulators, working independently, reached the same conclusion. That convergence is itself evidence.

What should patients and clinicians do now?

Don't panic, but don't ignore it either.

The risk is real — every piece of evidence points the same direction. Yet the absolute number of people likely to develop the side effect is small. For anyone using the medication for an FDA-approved condition such as diabetes or obesity on a doctor's advice, the risk should not deter continued use, according to Ziyad Al-Aly, a clinical epidemiologist at Washington University in St. Louis whose research helped identify the link.

The practical guidance is straightforward:

  • Clinicians should discuss the risk before prescribing a GLP-1 drug
  • Patients should learn the symptoms of NAION and how to recognize them
  • Anyone experiencing vision problems should seek immediate care
  • Patients with a previous NAION episode, or with risk factors — smoking, diabetes, high blood pressure, sleep apnea, anemia, kidney disease — should have a careful risk-benefit discussion with their doctor

The FDA's warning is best read not as an alarm but as an unlikely, not impossible, outcome that both clinicians and patients simply need on their radar.

via fortune.com/feed/ (Source)

Share this article:

More from Priya Raman

Priya Raman

Show full bio

Senior reporter covering technology and product news in corporate strategy and chief-executive leadership at CEO Frontier.

460 articles

Filed under

Adjacent sheets

« Previous articleNext article »

End of sheetW-95 / M2 · November 17, 2026